Glycogen synthase kinase 3β inhibition sensitizes human glioblastoma cells to temozolomide by affecting O6-methylguanine DNA methyltransferase promoter methylation via c-Myc signaling.

No abstract is available for this paper.

• Publication year

  2013

• Venue

  Carcinogenesis

• Publication date

  2013-10-01

• Fields of study

  Biology, Medicine, Chemistry

• Identifiers
  DOI 10.1093/carcin/bgt182PMID 23715499
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• A Combined Preclinical Therapy of Cannabinoids and Temozolomide against Glioma

  2011cited by this paper
• The Pivotal Roles of GSK3β in Glioma Biology

  2011cited by this paper
• The correlation between promoter methylation status and the expression level of O6-methylguanine-DNA methyltransferase in recurrent glioma.

  2011cited by this paper
• In vivo assessment of temozolomide local delivery for lung cancer inhalation therapy.

  2010cited by this paper
• Sphingosine‐1‐phosphate receptor type 1 regulates glioma cell proliferation and correlates with patient survival

  2010cited by this paper
• An emerging strategy for cancer treatment targeting aberrant glycogen synthase kinase 3 beta.

  2009cited by this paper
• Potential Therapeutic Effect of Glycogen Synthase Kinase 3β Inhibition against Human Glioblastoma

  2009influential reference
• Glycogen synthase kinase-3: a new therapeutic target in renal cell carcinoma

  2009cited by this paper
• Glycogen synthase kinase-3 inhibition induces glioma cell death through c-MYC, nuclear factor-kappaB, and glucose regulation.

  2008influential reference
• The 2007 WHO Classification of Tumours of the Central Nervous System

  2007cited by this paper
• Theoretical Basis, Experimental Design, and Computerized Simulation of Synergism and Antagonism in Drug Combination Studies

  2006cited by this paper
• EphB2/R-Ras signaling regulates glioma cell adhesion, growth, and invasion.

  2005cited by this paper
• MGMT gene silencing and benefit from temozolomide in glioblastoma.

  2005influential reference
• Myc represses transcription through recruitment of DNA methyltransferase corepressor

  2005cited by this paper
• Brain tumors

  2005cited by this paper
• Analysis of repetitive element DNA methylation by MethyLight

  2005cited by this paper
• Two-step cross-linking method for identification of NF-kappaB gene network by chromatin immunoprecipitation.

  2005cited by this paper
• Temozolomide Pharmacodynamics in Patients with Metastatic Melanoma: DNA Damage and Activity of Repair Enzymes O6-Alkylguanine Alkyltransferase and Poly(ADP-Ribose) Polymerase-1

  2005cited by this paper
• Possible future issues in the treatment of glioblastomas: special emphasis on cell migration and the resistance of migrating glioblastoma cells to apoptosis.

  2005cited by this paper
• The glamour and gloom of glycogen synthase kinase-3.

  2004cited by this paper
• Plasma and Cerebrospinal Fluid Population Pharmacokinetics of Temozolomide in Malignant Glioma Patients

  2004cited by this paper
• Regulated subset of G1 growth-control genes in response to derepression by the Wnt pathway

  2003cited by this paper
• An integrated database of genes responsive to the Myc oncogenic transcription factor: identification of direct genomic targets

  2003cited by this paper
• Inhibition of DNA repair for sensitizing resistant glioma cells to temozolomide.

  2003cited by this paper
• Phosphorylation by Glycogen Synthase Kinase-3 Controls c-Myc Proteolysis and Subnuclear Localization*

  2003cited by this paper
• Structural Insights and Biological Effects of Glycogen Synthase Kinase 3-specific Inhibitor AR-A014418*

  2003cited by this paper
• Chemotherapy in adult high-grade glioma: a systematic review and meta-analysis of individual patient data from 12 randomised trials.

  2002cited by this paper
• p53 effects both the duration of G2/M arrest and the fate of temozolomide-treated human glioblastoma cells.

  2001cited by this paper
• Identification and validation of P311 as a glioblastoma invasion gene using laser capture microdissection.

  2001cited by this paper
• Adenocarcinoma Epigenetic Patterns in the Progression of Esophageal Updated Version

  2001cited by this paper
• Brain tumors.

  2001cited by this paper
• Abrogation of the Chk1-mediated G(2) checkpoint pathway potentiates temozolomide-induced toxicity in a p53-independent manner in human glioblastoma cells.

  2001cited by this paper
• Predicting lung cancer by detecting aberrant promoter methylation in sputum.

  2000cited by this paper
• O6‐methylguanine‐DNA methyltransferase gene (MGMT) expression in human glioblastomas in relation to patient characteristics and p53 accumulation

  1999cited by this paper
• Detection of weak estrogenic flavonoids using a recombinant yeast strain and a modified MCF7 cell proliferation assay.

  1998cited by this paper
• c-Myc and apoptosis.

  1995cited by this paper
• Identification of a Myc‐dependent step during the formation of active G1 cyclin‐cdk complexes.

  1995cited by this paper
• Site-specific modulation of c-Myc cotransformation by residues phosphorylated in vivo.

  1994cited by this paper
• Graded methylation in the promoter and body of the O6-methylguanine DNA methyltransferase (MGMT) gene correlates with MGMT expression in human glioma cells.

  1994cited by this paper
• Constitutive c-myc expression in an IL-3-dependent myeloid cell line suppresses cell cycle arrest and accelerates apoptosis.

  1991cited by this paper
• Quantitative analysis of dose-effect relationships: the combined effects of multiple drugs or enzyme inhibitors.

  1984cited by this paper
• The classification of tumours of the central nervous system.

  1982cited by this paper
• Exploitable mechanisms in combined radiotherapy-chemotherapy: the concept of additivity.

  1979cited by this paper

• Structure-Based Discovery Targeting GSK-3α Reveals Potent Nanomolar Selective 4-Phenyl-1H-benzofuro[3,2-b]pyrazolo[4,3-e]pyridine Inhibitor with Promising Glioblastoma and CNS-Active Potential in Cellular Models.

  2025cites this paper
• VP3.15, a dual GSK-3β/PDE7 inhibitor, reduces glioblastoma tumor growth though changes in the tumor microenvironment in a PTEN wild-type context

  2025cites this paper
• MGMT inhibition regulates radioresponse in GBM, GSC, and melanoma

  2024cites this paper
• The many faceted role of glycogen synthase kinase-3 (GSK-3) in T cells and cancer immunotherapy

  2024cites this paper
• Targeting epigenetic mechanisms of resistance to chemotherapy in gliomas.

  2024cites this paper
• MGMT in TMZ-based glioma therapy: Multifaceted insights and clinical trial perspectives.

  2024cites this paper
• The “Superoncogene” Myc at the Crossroad between Metabolism and Gene Expression in Glioblastoma Multiforme

  2023cites this paper
• Pharmacological Modulation of the Cytosolic Oscillator Affects Glioblastoma Cell Biology

  2023cites this paper
• Long non-coding RNA in glioma: novel genetic players in temozolomide resistance

  2023cites this paper
• Decrypting a path based approach for identifying the interplay between PI3K and GSK3 signaling cascade from the perspective of cancer

  2022cites this paper
• An oncogenic splice variant of PDGFRα in adult glioblastoma as a therapeutic target for selective CDK4/6 inhibitors

  2022cites this paper
• GSK3β palmitoylation mediated by ZDHHC4 promotes tumorigenicity of glioblastoma stem cells in temozolomide-resistant glioblastoma through the EZH2–STAT3 axis

  2022cites this paper
• Applications of noncoding RNAs in brain cancer patients

  2022cites this paper
• Emerging Epigenetic Therapies for Brain Tumors

  2021cites this paper
• Crosstalk of the Wnt/β-Catenin Signaling Pathway in the Induction of Apoptosis on Cancer Cells

  2021cites this paper
• Identifying Novel Actionable Targets in Colon Cancer

  2021cites this paper
• The embryonic stem cell microenvironment inhibits mouse glioma cell proliferation by regulating the PI3K/AKT pathway

  2021cites this paper
• Salidroside overcomes dexamethasone resistance in T-acute lymphoblastic leukemia cells

  2021cites this paper
• The multi-target small-molecule inhibitor SB747651A shows in vitro and in vivo anticancer efficacy in glioblastomas

  2021cites this paper
• Lithium and Therapeutic Targeting of GSK-3

  2021cites this paper
• GSK3β: A Master Player in Depressive Disorder Pathogenesis and Treatment Responsiveness

  2020cites this paper
• Identification of 2-fluoropalmitic acid as a potential therapeutic agent against glioblastoma.

  2020cites this paper
• Glycogen synthase kinase 3β in tumorigenesis and oncotherapy

  2020cites this paper
• Drug Repositioning for the Treatment of Glioma: Current State and Future Perspective

  2020cites this paper
• GSK-3β in DNA repair, apoptosis, and resistance of chemotherapy, radiotherapy of cancer.

  2020cites this paper
• Glycogen Synthase Kinase 3β in Cancer Biology and Treatment

  2020cites this paper
• C-Myc signaling pathway in treatment and prevention of brain tumors.

  2020cites this paper
• Glycogen synthase kinase‐3β participates in acquired resistance to gemcitabine in pancreatic cancer

  2020cites this paper
• Molecular and Cellular Complexity of Glioma. Focus on Tumour Microenvironment and the Use of Molecular and Imaging Biomarkers to Overcome Treatment Resistance

  2020cites this paper
• Potential therapeutic effect of targeting glycogen synthase kinase 3β in esophageal squamous cell carcinoma

  2020cites this paper
• Differential Effects of Ang-2/VEGF-A Inhibiting Antibodies in Combination with Radio- or Chemotherapy in Glioma

  2019cites this paper
• Glycogen synthase kinases: Moonlighting proteins with theranostic potential in cancer.

  2019cites this paper
• Wnt-signaling pathway in pathogenesis of glioblastoma multiforme

  2019cites this paper
• Glycogen synthase kinase-3 beta inhibitors as novel cancer treatments and modulators of antitumor immune responses

  2019cites this paper
• Regulation of AKT phosphorylation by GSK3β and PTEN to control chemoresistance in breast cancer

  2019cites this paper
• Sirtuin 1 knockdown inhibits glioma cell proliferation and potentiates temozolomide toxicity via facilitation of reactive oxygen species generation

  2019cites this paper
• Identification of GSK3β inhibitor kenpaullone as a temozolomide enhancer against glioblastoma

  2019cites this paper
• CRMP2 Phosphorylation Drives Glioblastoma Cell Proliferation

  2018cites this paper
• Temozolomide treatment of a malignant pheochromocytoma and an unresectable MAX-related paraganglioma

  2018cites this paper
• Potential Strategies Overcoming the Temozolomide Resistance for Glioblastoma

  2018cites this paper
• Glycogenolysis in Acquired Glioma Resistance to Temozolomide: A Role for the [Ca2+]i-dependent Activation of Na,K-ATPase/ERK1/2 Signaling

  2018cites this paper
• Long noncoding RNA MALAT1 knockdown reverses chemoresistance to temozolomide via promoting microRNA‐101 in glioblastoma

  2018cites this paper
• Pyrrolidine dithiocarbamate sensitizes U251 brain glioma cells to temozolomide via downregulation of MGMT and BCL-XL

  2017cites this paper
• Drug repositioning in Neuro-Oncology

  2017cites this paper
• Targeting Protein Kinases for the Treatment of Glioblastoma Multiforme: Linking Basic Studies to Clinical Applications.

  2017cites this paper
• Glioblastoma and chemoresistance to alkylating agents: Involvement of apoptosis, autophagy, and unfolded protein response

  2017cites this paper
• Chromatin Remodeling Factor LSH is Upregulated by the LRP6-GSK3β-E2F1 Axis Linking Reversely with Survival in Gliomas

  2017cites this paper
• Formation and degradation of nitrogen mustard-induced MGMT-DNA crosslinking in 16HBE cells.

  2017cites this paper
• Biological basis and clinical study of glycogen synthase kinase- 3β-targeted therapy by drug repositioning for glioblastoma

  2017cites this paper
• KLRC3, a Natural Killer receptor gene, is a key factor involved in glioblastoma tumourigenesis and aggressiveness

  2016cites this paper
• Downregulation of HIF-1a sensitizes U251 glioma cells to the temozolomide (TMZ) treatment.

  2016cites this paper
• Phosphatidylinositol 3-Kinase/AKT Pathway Inhibition by Doxazosin Promotes Glioblastoma Cells Death, Upregulation of p53 and Triggers Low Neurotoxicity

  2016cites this paper
• Tokuda Akihiro Tomida Shinya Toyokuni Hitoshi Tsuda Shoichiro Tsugane Tatsuhiko Tsunoda Heiichiro Udono Koji Ueda Yoshimasa Uehara Hiroo Ueno Kazuo Umezawa Toshikazu Ushijima Toshihiko Wakabayashi Kenji Wakai Tetsuro Watabe

  2016cites this paper
• MicroRNA-101 reverses temozolomide resistance by inhibition of GSK3β in glioblastoma

  2016cites this paper
• Efficacy of glycogen synthase kinase-3β targeting against osteosarcoma via activation of β-catenin

  2016cites this paper
• Glycogen synthase kinase‐3β is a pivotal mediator of cancer invasion and resistance to therapy

  2016cites this paper
• DNA repair mechanisms and their clinical impact in glioblastoma.

  2016cites this paper
• Pterostilbene suppressed irradiation-resistant glioma stem cells by modulating GRP78/miR-205 axis.

  2015cites this paper
• Loss of Glycogen Synthase Kinase 3 Isoforms During Murine Oocyte Growth Induces Offspring Cardiac Dysfunction 1 Running title - Absence of oocyte GSK3 and neonatal death

  2015cites this paper
• Loss of Glycogen Synthase Kinase 3 Isoforms During Murine Oocyte Growth Induces Offspring Cardiac Dysfunction1

  2015cites this paper
• Mitochondrial Impairment May Increase Cellular NAD(P)H: Resazurin Oxidoreductase Activity, Perturbing the NAD(P)H-Based Viability Assays

  2015cites this paper
• Localized RNAi therapeutics of chemoresistant grade IV glioma using hyaluronan-grafted lipid-based nanoparticles.

  2015cites this paper
• The role of Myc and let-7a in glioblastoma, glucose metabolism and response to therapy.

  2015cites this paper
• Could the Anti-Chaperone VER155008 Replace Temozolomide for Glioma Treatment

  2015cites this paper
• c-Myc-miR-29c-REV3L signalling pathway drives the acquisition of temozolomide resistance in glioblastoma.

  2015cites this paper
• Epigenetic regulation of adult neural stem cells: implications for Alzheimer’s disease

  2014cites this paper
• Quercetin sensitizes human glioblastoma cells to temozolomide in vitro via inhibition of Hsp27

  2014cites this paper
• JNK contributes to temozolomide resistance of stem-like glioblastoma cells via regulation of MGMT expression.

  2014cites this paper
• Glycogen Synthase Kinase 3β Sustains Invasion of Glioblastoma via the Focal Adhesion Kinase, Rac1, and c-Jun N-Terminal Kinase-Mediated Pathway

  2014cites this paper
• This Provisional PDF corresponds to the article as it appeared upon acceptance. Fully formatted PDF and full text (HTML) versions will be made available soon. Epigenetic regulation of adult neural stem cells: implications for Alzheimer's disease

  2014cites this paper
• GSK-3 as potential target for therapeutic intervention in cancer

  2014cites this paper
• Epigenetic regulation of adult neural stem cells : implications for Alzheimer ’ s disease

  2014cites this paper